KRABS Biotechnology is a startup focused in development of new antibodies phage display technique and a human scFv phage library. We operate in several areas of biotechnology, such as human and animal health, drug development, IVD, environmental monitoring and pathogen detection.

Using a new chimeric antibody, KRABS is developing a new topical drug to treat Atopic Dermatitis, which should reach preclinical trials by 2025, clinical trials by 2026 and the market by 2028.

Contact us to learn more about KRABS Biotechnology, our pipeline and the opportunity of investment in a highly innovative first-in-class drug, with patent application in USA, Europe and Brazil.